News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Daiichi Sankyo Co Ltd. Says Offer for Ranbaxy Laboratories Oversubscribed
September 24, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Sept 24 (Reuters) - Japan's third-largest drugmaker Daiichi Sankyo Co said on Wednesday its open offer to buy up to 20 percent of India's generic drugmaker Ranbaxy Laboratories Ltd was oversubscribed.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
Daiichi Sankyo
MORE ON THIS TOPIC
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
December 10, 2025
·
1 min read
·
Heather McKenzie
Obesity
After Metsera Battle, Pfizer Heads to China for Another Obesity Deal Worth up to $1.9B
December 9, 2025
·
2 min read
·
Dan Samorodnitsky
China
With Chinese Assets in Hand, Pharma Is Wondering What Else Can Be Learned
December 9, 2025
·
3 min read
·
Annalee Armstrong
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
December 4, 2025
·
2 min read
·
Tristan Manalac
